Merck's Licensing & External Research Director Jennifer Hu On Choosing Partners In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Big pharma's rush into emerging markets is bringing more R&D to these markets, and as one of the key emerging markets China has attracted most multinational companies to set their R&D and licensing footprint here. Jennifer Hu, Merck's director of licensing and external research, recently shared her thoughts with PharmAsia News' Shanghai bureau about Merck's partnering and licensing strategy in China.
You may also be interested in...
China Leads Pharmaceutical Growth In 2009: Asia Pharma R&D Leaders
SHANGHAI - While China's most influential meeting - the eleventh National People's Congress of China - prepares to open its third session in Beijng March 5, pharma R&D leaders gathered in Shanghai to discuss the future of the pharmaceutical industry
China Leads Pharmaceutical Growth In 2009: Asia Pharma R&D Leaders
SHANGHAI - While China's most influential meeting - the eleventh National People's Congress of China - prepares to open its third session in Beijng March 5, pharma R&D leaders gathered in Shanghai to discuss the future of the pharmaceutical industry
Merck's Chief Strategy Officer Mervyn Turner Talks To PharmAsia News About Partnerships And Transformational Research Models
Mervyn J. Turner, Merck's chief strategy officer and senior vice president for emerging markets is entrusted with the responsibility of forging research partnerships with companies across the globe. Turner evaluates pipelines and capabilities of companies that can benefit the core drug discovery functions at Merck's laboratories and as part of that function, he is building partnerships with companies in India such as Ranbaxy, Piramal Healthcare, Orchid and Advinus. On a visit to India recently, Turner sat down with PharmAsia News' India bureau to elaborate on his future ideas.